EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2

Yongwei Lai, Xu Han, Bo Xie, Yan Xu, Zhengyi Yang, Didi Wang, Wei Li, Yaohong Xie, Wenqi Song, Xiaohong Zhang, Jia Qi Xia iD, Pengxia Zhang iD

Cancer Science · 2024-07 · 115 (7) · 2220-2234

DOI: 10.1111/cas.16186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, online erschienen am 16.04.2024. Verfasst von Yongwei Lai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Microecology-Immune Regulatory Network and Related Diseases School of Basic Medicine, Jiamusi University, Jiamusi, China. Hauptthemen laut MEDLINE: Sorafenib, Enhancer of Zeste Homolog 2 Protein, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Heilongjiang Province new round of advantageous and characteristic discipline project "northern medicine and functional food"., National Ministry of Science and Technology High end Foreign Expert Introduction Program, Heilongjiang Province Double First Class Discipline Collaborative Innovation Achievement Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Enhancing sensitivity to sorafenib can significantly extend the duration of resistance to it, offering substantial benefits for treating patients with hepatocellular carcinoma (HCC). However, the role of ferroptosis in influencing sorafenib sensitivity within HCC remains pivotal. The enhancer of zeste homolog 2 (EZH2) plays a significant role in promoting malignant progression in HCC, yet the relationship between ferroptosis, sorafenib sensitivity, and EZH2 is not entirely clear. Bioinformatic analysis indicates elevated EZH2 expression in HCC, predicting an unfavorable prognosis. Overexpressing EZH2 can drive HCC cell proliferation while simultaneously reducing ferroptosis. Further analysis reveals that EZH2 amplifies the modification of H3K27 me3, thereby influencing TFR2 expression. This results in decreased RNA polymerase II binding within the TFR2 promoter region, leading to reduced TFR2 expression. Knocking down EZH2 amplifies sorafenib sensitivity in HCC cells. In sorafenib‐resistant HepG2(HepG2‐SR) cells, the expression of EZH2 is increased. Moreover, combining tazemetostat—an EZH2 inhibitor—with sorafenib demonstrates significant synergistic ferroptosis‐promoting effects in HepG2‐SR cells. In conclusion, our study illustrates how EZH2 epigenetically regulates TFR2 expression through H3K27 me3, thereby suppressing ferroptosis. The combination of the tazemetostat with sorafenib exhibits superior synergistic effects in anticancer therapy and sensitizes the HepG2‐SR cells to sorafenib, shedding new light on delaying and ameliorating sorafenib resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibEnhancer of Zeste Homolog 2 ProteinCarcinoma, HepatocellularLiver NeoplasmsFerroptosisEpigenesis, GeneticDrug Resistance, NeoplasmHumansHep G2 CellsMiceGene Expression Regulation, NeoplasticAnimalsPyridonesReceptors, TransferrinCell ProliferationCell Line, TumorMorpholinesBenzamidesBiphenyl Compounds

Stichwörter der Autor:innen

EZH2TFR2ferroptosishepatocellular carcinomasorafenib

Substanzen

SorafenibEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanPyridonesReceptors, TransferrintazemetostatMorpholinesBenzamidesBiphenyl Compounds

Autor:innen und Institutionen

  • Key Laboratory of Microecology-Immune Regulatory Network and Related Diseases School of Basic Medicine, Jiamusi University, Jiamusi, China.
  • School of Clinical Medicine, Jiamusi University, Jiamusi, China.
  • Department of Basic Medicine, Jiangsu Vocational College of Medicine, Yancheng, China.

ORCID-Profile: Jia Qi Xia, Pengxia Zhang

Förderung

  • Heilongjiang Province new round of advantageous and characteristic discipline project "northern medicine and functional food".
  • National Ministry of Science and Technology High end Foreign Expert Introduction Program
  • Heilongjiang Province Double First Class Discipline Collaborative Innovation Achievement Project
  • Horizontal Project of Jiangsu Vocational College of Medical
  • Heilongjiang Natural Science Foundation Joint Guidance Project

Zitieren

APA

Lai, Y., Han, X., Xie, B., Xu, Y., Yang, Z., Wang, D., Li, W., Xie, Y., Song, W., Zhang, X., Xia, J. Q., & Zhang, P. (2024). EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2. Cancer Science, 115(7), 2220-2234. https://doi.org/10.1111/cas.16186

Vancouver

Lai Y, Han X, Xie B, Xu Y, Yang Z, Wang D, et al. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2. Cancer Science. 2024;115(7):2220-2234. doi:10.1111/cas.16186

BibTeX
@article{Lai2024,
  author = {Lai, Yongwei and Han, Xu and Xie, Bo and Xu, Yan and Yang, Zhengyi and Wang, Didi and Li, Wei and Xie, Yaohong and Song, Wenqi and Zhang, Xiaohong and Xia, Jia Qi and Zhang, Pengxia},
  title = {EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2},
  journal = {Cancer Science},
  year = {2024},
  volume = {115},
  number = {7},
  pages = {2220--2234},
  doi = {10.1111/cas.16186}
}
Kostenlos starten →